See more : NextEra Energy, Inc. Series N J (NEE-PN) Income Statement Analysis – Financial Results
Complete financial analysis of Medicenna Therapeutics Corp. (MDNA.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicenna Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Chigo Holding Limited (0449.HK) Income Statement Analysis – Financial Results
- Baker Hughes Company (68V.DE) Income Statement Analysis – Financial Results
- OFX Group Limited (OFX.AX) Income Statement Analysis – Financial Results
- Hagihara Industries Inc. (7856.T) Income Statement Analysis – Financial Results
- Sandoz Group AG (SDZ.SW) Income Statement Analysis – Financial Results
Medicenna Therapeutics Corp. (MDNA.TO)
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 5.00K | 38.00K | 40.00K | 7.89K | 6.82K | 9.70K | 6.49K | 1.44K | 0.00 | 0.00 |
| Gross Profit | -5.00K | -5.00K | -38.00K | -40.00K | -7.89K | -6.82K | -9.70K | -6.49K | -1.44K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.79M | 9.30M | 14.72M | 10.87M | 5.87M | 3.02M | 5.09M | 4.23M | 771.41K | 766.30K | 860.96K |
| General & Administrative | 7.87M | 6.99M | 7.72M | 6.49M | 2.49M | 2.21M | 3.00M | 4.02M | 469.71K | 253.11K | 112.62K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.87M | 6.99M | 7.72M | 6.49M | 2.49M | 2.21M | 3.00M | 4.02M | 469.71K | 253.11K | 112.62K |
| Other Expenses | 0.00 | 5.00K | 37.00K | 40.00K | -117.48K | -499.37K | -661.94K | -547.40K | -41.45K | 0.00 | 0.00 |
| Operating Expenses | 19.66M | 16.30M | 22.47M | 17.40M | 8.24M | 4.73M | 7.42M | 7.70M | 1.20M | 833.31K | 767.69K |
| Cost & Expenses | 19.66M | 16.30M | 22.47M | 17.40M | 8.24M | 4.73M | 7.42M | 7.70M | 1.20M | 833.31K | 767.69K |
| Interest Income | 1.20M | 914.00K | 69.00K | 314.00K | 6.73K | 102.00 | 0.00 | 32.80K | 0.00 | 0.00 | 1.92 |
| Interest Expense | 0.00 | 0.00 | 69.00K | 0.00 | 0.00 | 0.00 | 0.00 | 60.00 | 441.00 | 0.18 | 0.00 |
| Depreciation & Amortization | 5.00K | 5.00K | 38.00K | 40.00K | 7.89K | 6.82K | 9.70K | 6.49K | 1.44K | 718.00 | 762.00K |
| EBITDA | -18.67M | -16.30M | -22.54M | -17.25M | -8.27M | -4.70M | -7.46M | -7.62M | -1.20M | -828.39K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.66M | -21.64M | -22.30M | -17.19M | -8.21M | -4.73M | -7.42M | -7.70M | -1.20M | -829.11K | -762.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.80M | 7.00M | 1.65M | 106.00K | 919.00K | 5.16M | 4.98M | 350.15K | 1.34M | 185.91K | 207.81K |
| Income Before Tax | -25.47M | -10.05M | -22.58M | -17.29M | -8.28M | -4.71M | -7.47M | -7.63M | -1.33M | -833.49K | -765.77K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -11.60M | 69.00K | -106.00K | 32.27K | 19.25K | 40.62K | 60.00 | 441.00 | 0.00 | -3.77 |
| Net Income | -25.47M | 1.55M | -22.65M | -17.18M | -8.31M | -4.71M | -7.47M | -7.63M | -1.33M | -833.49K | -765.77K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.37 | 0.02 | -0.42 | -0.35 | -0.26 | -0.18 | -0.31 | -0.45 | -0.08 | -0.05 | -0.05 |
| EPS Diluted | -0.37 | 0.02 | -0.42 | -0.35 | -0.26 | -0.18 | -0.31 | -0.45 | -0.08 | -0.05 | -0.05 |
| Weighted Avg Shares Out | 69.64M | 64.74M | 54.29M | 49.66M | 31.90M | 25.67M | 24.37M | 16.91M | 16.00M | 15.60M | 15.60M |
| Weighted Avg Shares Out (Dil) | 69.64M | 64.74M | 54.29M | 49.66M | 31.90M | 25.67M | 24.37M | 16.91M | 16.00M | 15.60M | 15.60M |
Source: https://incomestatements.info
Category: Stock Reports